News
Advaxis' Dr. John Rothman to Present at the Bio International Convention in San Diego, CA
NORTH BRUNSWICK, N.J.-(Business Wire)-June 18, 2008 - Dr. John Rothman CEO of Advaxis Inc., (OTCBB: ADXS), a developmental biotechnology company, is scheduled to present at the BIO International Convention (BIO) today, Wednesday, June 18, 2008, at 1:00PM PDT in the GEN Theater. Dr. Rothman's presentation, entitled "The Use Of Bioengineered Listeria Monocytogenes As A Live Cancer Vaccine," will detail how modified live Listeria bacteria is being used as the vector to target cervical and prostate cancer.
The world's largest gathering of the biotechnology industry, BIO is a symposium that features leading pharmaceutical and biotechnology companies presenting emerging sector trends to institutional investors, portfolio managers, analysts, and the media.
"We are delighted to have the opportunity to present our recent findings at this year's BIO International Convention," said Dr. Rothman. "We are confident that this presentation will capitalize on the excitement surrounding potential use of Listeria as a live cancer vaccine, as recently reported in such major media outlets as U.S. News & World Report, CNBC, Forbes, Popular Science, Scientific American, MarketWatch, the Wall Street Journal."
About the 2008 BIO International Convention
The 2008 BIO International Convention, hosted by the Biotechnology Industry Organization, reflects the growing promise of biotechnology and innovative solutions to help heal, fuel and feed the world and provide a cleaner environment. The convention will feature keynotes from industry and global leaders, more than 175 breakout sessions, business partnering meetings, and numerous networking events. The convention also includes more than 200,000 square feet of exhibitions showcasing the latest advancements in biotechnology alongside an array of potential partners, service providers, and state and international delegations.
The BIO International Convention is where the global biotechnology community comes together to address key issues and make the vital connections needed to drive future innovations aimed at improving global health and overall quality of life in all regions of the world. BIO anticipates more than 20,000 industry leaders, government officials, and others will attend the convention. In 2007, the convention attracted 22,366 attendees and exhibitors with approximately one-third from countries outside the U.S. The 2007 event also hosted more than 300 domestic and international public officials including seven U.S. governors.
The BIO International Convention is the world's largest gathering of the biotechnology industry attended by more than 20,000 participants. The convention is a blend of international and domestic executives and management from research, business, academic, and investment communities. For more information, please visit www.bio2008.org.
About Advaxis, Inc.
Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria monocytogenes ("Lm") cancer vaccines based on technology developed by Dr. Yvonne Paterson, Professor of Microbiology at the University of Pennsylvania and Chairperson of Advaxis' Scientific Advisory Board. Advaxis is developing therapeutic cancer vaccines that enhance the immune system's cancer fighting abilities through its proprietary Lm based system, which utilizes multiple simultaneous immunological mechanisms to fight cancer safely.
Advaxis' lead Listeria vaccine candidate, Lovaxin C, targets HPV-associated cancers such as cervical and head and neck. Current Lm vaccines in development target prostate, breast, and ovarian and other cancers. Recently, Advaxis completed a Phase I/II clinical trial of Lovaxin C. A Phase II clinical trial is planned for patients with cervical intraepithelial neoplasia ("CIN"). The company intends to start this study in CIN I/II patients in the summer of 2008. The Lm platform also has applications in the fields of infectious disease and autoimmune disorders.
For further information on the Company, please visit: http://www.advaxis.com.
About Lovaxin C Vaccine
Advaxis' Listeria technology platform uses modified Listeria monocytogenes to deliver a tumor-specific antigen fusion protein. Bioengineered Listeria that are attenuated and secrete Advaxis' proprietary fusion protein, have the ability to generate a robust immune response, break immune tolerance to cancer and produce an unusually strong and effective multi-level therapeutic immune response to existing cancer and other diseases.
Advaxis' Listeria-based technology is based on over a decade's worth of work by Dr. Yvonne Paterson in her laboratory at the University of Pennsylvania. The Company's proprietary antigen fusion protein technology, stimulates innate immunity, both arms of the adaptive cellular immune system, suppresses regulatory T cells that inhibit many vaccines in the function of activated tumor-killing cells and has other anti-tumor effects.
Unlike prophylactic vaccines, Lovaxin C was designed to treat women who have already developed cervical cancer as a result of contracting a human papilloma virus ("HPV") infection, which is the most prevalent sexually transmitted disease in the US. Current products on the market are ineffective in treating HPV-infected women.
For further information on Lovaxin C, please visit: http://www.advaxis.com/lc.htm
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
 |
 |
 |
|
||
 |
|
 |
|
||
Search Our News Using Google Search
Can't find what you want? Try using Google:
